Subsequent Events (Details) - Subsequent Events [Member] - USD ($)		1 Months Ended
	Nov. 03, 2025	Nov. 07, 2025	Oct. 31, 2025
Subsequent Events [Abstract]
Proceeds from exercise of warrants (in Dollars)		$ 3,115,000
November 2023 Financing [Member]
Subsequent Events [Abstract]
Proceeds from convertible notes (in Dollars)	$ 12,000,000
Pre Funded Warrants [Member]
Subsequent Events [Abstract]
Warrants issued to purchase common stock (in Shares)			707,620
Warrants exercise price (in Dollars per share)			$ 0.0001
Common Warrants [Member]
Subsequent Events [Abstract]
Warrants issued to purchase common stock (in Shares)		8,652,777
Warrants exercise price (in Dollars per share)		$ 0.36
November 2025 Notes [Member] \| November 2023 Financing [Member]
Subsequent Events [Abstract]
Convertible note accrue interest rate	8.50%
Frequency of installment payments	annually
Maturity period	10 years
Common Stock [Member] \| November 2025 Notes [Member] \| November 2023 Financing [Member]
Subsequent Events [Abstract]
Aggregate principal amount (in Dollars)	$ 12,000,000
Number of shares issued upon conversion of convertible notes (in Shares)	16,378,563
Conversion price (in Dollars per share)	$ 0.73
Series A-1 Warrants [Member] \| November 2023 Financing [Member]
Subsequent Events [Abstract]
Warrants issued to purchase common stock (in Shares)	16,378,563
Warrants exercise price (in Dollars per share)	$ 0.81
Maturity period	10 years
Series B-1 Warrants [Member] \| November 2023 Financing [Member]
Subsequent Events [Abstract]
Warrants issued to purchase common stock (in Shares)	16,378,563
Warrants exercise price (in Dollars per share)	$ 0.92
Maturity period	10 years
Series C-1 Warrants [Member] \| November 2023 Financing [Member]
Subsequent Events [Abstract]
Warrants issued to purchase common stock (in Shares)	16,378,563
Warrants exercise price (in Dollars per share)	$ 1.1
Maturity period	10 years
At-the-Market Facility [Member]
Subsequent Events [Abstract]
Sale of common stock (in Shares)	1,817,054
Gross proceeds (in Dollars)	$ 1,516,371

FEMASYS INC 10-Q